Pneumococcal conjugate vaccines - implications for community antibiotic prescribing.
Infections caused by Streptococcus pneumoniae are a major cause of morbidity and mortality in the pediatric population worldwide. Development of increasing resistance to multiple classes of antibiotics is making treatment of infections caused by this organism much more difficult. In order to prevent disease, a 23-valent pneumococal polysaccharide vaccine is available. However, this vaccine is poorly immunogenic in infants and young children. The development and licensing of pneumococcal conjugate vaccines that are safe and effective in the pediatric population is an important step in our ability to decrease the prevalence of pneumococcal disease seen.
Tan
T Q
TQ
Northwestern University Medical School, Division of Infectious Diseases, The Children's Memorial Hospital, 2300 Children's Plaza, Box 20, Chicago, IL 60614, USA. ttan@nwu.edu
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003140:Communicable Disease Control / Q000639:trends; D006801:Humans; D011008:Pneumococcal Infections / Q000628:therapy*; D022242:Pneumococcal Vaccines / Q000627:therapeutic use*; D011135:Polysaccharides, Bacterial / Q000627:therapeutic use; D018074:Vaccines, Conjugate / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial; D018074:Vaccines, Conjugate